middle.news

CLINUVEL Hits 200-Patient Mark in Pivotal Vitiligo Trial, Eyes 2026 Data

3:07am on Monday 2nd of June, 2025 AEST Healthcare
Read Story

CLINUVEL Hits 200-Patient Mark in Pivotal Vitiligo Trial, Eyes 2026 Data

3:07am on Monday 2nd of June, 2025 AEST
Key Points
  • Full recruitment of 200 vitiligo patients achieved in Phase III CUV105 trial
  • Trial spans 37 sites across North America, Africa, and Europe
  • Treatment combines SCENESSE® with NB-UVB phototherapy or NB-UVB alone
  • First clinical case studies show encouraging repigmentation and tolerability
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Clinuvel Pharmaceuticals (ASX:CUV)
OPEN ARTICLE